Product Type (Peripheral Anesthesia Disposables, Combined Spinal Epidural Disposables, Epidural Anesthesia Disposables and Spinal Anesthesia Disposables), End-User (Hospitals, Ambulatory Surgery Centers and Multispecialty Clinics), Trends, Industry Competition Analysis, Revenue and Forecast To 2034.â€?  According to the latest research by Insightace Analytics, the global regional anesthesia disposables market was valued at USD 404.87 million in 2024. It is expected to reach USD 651.93 million by 2034, with a CAGR of 5.0 % during a forecast period of 2025-2034.  Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1124  Regional anesthesia, unlike general anesthesia, provides localized numbness without affecting patient consciousness, making it ideal for a variety of targeted procedures. The adoption of disposable products in regional anesthesia offers significant advantages, including portability, user-friendliness, and versatility across both surgical and non-surgical applications.  These products are utilized in multiple specialties, including gastrointestinal, neurological, ophthalmic, urologic, cardiovascular, and orthopedic care. Additionally, disposable regional anesthesia devices are instrumental in non-operative pain management, addressing needs in trauma care, chronic pain therapy, critical care, and obstetrics. Their single-use design also reduces the risk of cross-contamination, thereby enhancing patient safety.  The regional anesthesia disposables market is experiencing robust growth, driven by several key factors. Rising global prevalence of chronic diseases, increasing volumes of surgical procedures, heightened awareness of advanced medical technologies, and growing demand for safe and effective pain managementâ€”particularly in surgical and maternity careâ€”are contributing to market expansion.  The high incidence of conditions such as neurological disorders, cardiovascular diseases, chronic respiratory ailments, cancer, and infectious diseases continues to fuel the need for effective anesthesia solutions. According to the World Health Organization (WHO), over 312.9 million surgical procedures were performed worldwide in 2018, with numbers projected to grow at a compound annual growth rate of 4.1%, further supporting demand for regional anesthesia disposables.  Ongoing advancements in research and development are expected to create new growth opportunities for market participants. The introduction of innovative product offerings is anticipated to reinforce the marketâ€™s positive trajectory over the coming years.  Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04  North America is anticipated to contribute to the regional anesthesia disposables market over the forecast years. The need for anesthetic disposables is driven by the regionâ€™s high prevalence of chronic diseases, rising surgical rates, and growing investments in the healthcare system. In addition, the Asia Pacific regional anesthesia disposables market is expected to grow significantly during the forecast period due to the regionâ€™s expanding patient population and rising surgical activity.  Major market players operating in the regional anesthesia disposables market include  Braun Medical Inc, Teleflex Inc., Smiths Group plc, Actuated Medical Inc, DOME Medical Technologies Inc, Becton Dickinson and Company, Pajunk GmbH, Vygon SA, Epimed, Flat Medical, Medovate Ltd, Omeq Medical Ltd., Safersonic US Inc., CIVCO Medical Solutions, Spectra Medical, HEKA healthcare, Egemen International, Unisis Corporation Japan, Vogt medical, SARSTEDT AG & CO, SFM Medical devices and Other Prominent Player.  Recent collaborations and agreements in the market:  In January 2021, ICU Medical declared that it had successfully purchased Smiths Medical from Smiths Group plc. The transaction focuses on building infrastructure and investing in integration to support the 2017 acquisition of Hospira Infusion Systems.  In October 2021, Medovate, a company specializing in cutting-edge medical technology research and commercialization, recently announced its first contract with Bluestone Corporation Pte Ltd in Asia to distribute SAFIRA (SAFer Injection for Regional Anesthesia) in the Singapore area.  Unlock Your GTM Strategy:  https://www.insightaceanalytic.com/customisation/1124  Market Segments  Global Regional Anesthesia Disposables Market, by Product Type, 2022-2028 (Value US$ Mn)  Peripheral Anesthesia Disposables Peripheral Nerve Block Needle  Catheters  Catheter Connector and Filter  Luer-Lock syringe  Ultrasound Probe Cover Set  Combined Spinal Epidural Disposables Spinal Needle  Epidural Needle  Epidural Catheter  Fixation Device  Epidural Anesthesia Disposables Continuous Epidural Anesthesia Kits  Epidural Catheter  Epidural Needle  Catheter Connector  Catheter Fixation and Filter  Syringe/ Luer Lock Syringe  Others (Balloon, Plastic Syringe, etc.)  Spinal Anesthesia Disposables Needles  Spinal Anesthesia Accessories Trays  Global Regional Anesthesia Disposables Market, by End User, 2022-2028 (Value US$ Mn)  Hospitals  Ambulatory Surgery Centers  Multispecialty Clinics  Global Regional Anesthesia Disposables Market, by Region, 2022-2028 (Value US$ Mn)  North America  Europe  Asia Pacific  Latin America  Middle East & Africa  North America Regional Anesthesia Disposables Market, by Country , 2022-2028 (Value US$ Mn)  S.  Canada  Europe Regional Anesthesia Disposables Market, by Country , 2022-2028 (Value US$ Mn)  Germany  France  Italy  Spain  Russia  Rest of Europe  Asia Pacific Regional Anesthesia Disposables Market, by Country , 2022-2028 (Value US$ Mn)  India  China  Japan  South Korea  Australia & New Zealand  Latin America Regional Anesthesia Disposables Market, by Country , 2022-2028 (Value US$ Mn)  Brazil  Mexico  Rest of Latin America  Middle East & Africa Regional Anesthesia Disposables Market, by Country , 2022-2028 (Value US$ Mn)  GCC Countries  South Africa  Rest of Middle East & Africa  Why should buy this report:  To receive a comprehensive analysis of the prospects for the global regional anesthesia disposables market  To receive an industry overview and future trends of the regional anesthesia disposables market  To analyze the regional anesthesia disposables market drivers and challenges  To get information on the regional anesthesia disposables market value (US$Mn) forecast to 2028  Significant investments, mergers & acquisitions in the regional anesthesia disposables market industry  About Us:  InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.  Tags: Regional Anesthesia Disposables Market See Campaign: https://www.insightaceanalytic.com/report/regional-anesthesia-disposables-market-size-share–trends-  Contact Information:  Contact us: InsightAce Analytic Pvt. Ltd. Visit: https://www.insightaceanalytic.com/ Tel : +1 607 400-7072 Asia: +91 79 72967118 info@insightaceanalytic.com  Tags:  CE, Go Media, Go Media2, iCN Internal Distribution, Reportedtimes, Research Newswire, English

Regional Anesthesia Disposables Market Insights Reveal Growth Driven by Single-Use Safety Advantages

Smart device aims to improve safety of epidurals
EpiFinder enhances, rather than replaces, the method doctors already use to deliver pain-relief meds to the space around spinal nerves. Epidurals are often used to block the pain of childbirth. Photo by Natalia Deriabina via Shutterstock.com
About 40 million epidural pain-relief injections are given annually worldwide, often administered to women in labor. An epidural involves injecting an anesthetic or a steroid into the space around the spinal nerves to stop pain signals from the spine reaching the brain. However, in 10-30 percent of cases the needle misses the correct spot on the first try. And in up to 5% of cases , the needle punctures the protective sac around the spinal fluid, leading to severe headaches and even neurological complications. Lior Margalit’s father was one of the unlucky ones. “My father broke his leg when he was in South America on a business trip and needed orthopedic surgery. Although the surgery went well, he suffered side effects from the placement of the needle during the epidural,” says Margalit. He decided to put his training as a biomedical engineer to the task. Margalit spoke with many anesthesiologists and researched the problems involved in epidural injections before cofounding Omeq Medical more than 10 years ago. Now, Omeq’s EpiFinder device has received regulatory clearance from the US Food and Drug Administration and will start being marketed early next year in the United States to assist physicians in accurately positioning epidural needles. Traditional and trailblazing
Unlike some other solutions on the market for this purpose, EpiFinder was designed to enhance, rather than replace, the method doctors already use. “Ours is the only real-time, objective indication for positioning that still allows doctors to use the standard technique,” Margalit tells ISRAEL21c. Since the 1920s, epidurals have been performed utilizing the loss of resistance (LOR) technique. The anesthesiologist advances the epidural needle forward until sensing a loss of resistance indicating that the needle reached the narrow epidural space in the spine. The success of LOR depends on the clinician’s experience, dexterity and tactile feedback. “Doctors understand that they’re using a very subjective technique and they miss from time to time and need to solve that problem,” Margalit learned from his early conversations with anesthesiologists. “But they wanted us to preserve their own technique at the same time. So we found a balance between tradition and innovation.”
The EpiFinder device. Photo courtesy of Omeq Medical
Instead of introducing a new technique or adding complexity to this already complex procedure, Omeq aims to improve LOR success with a battery-operated, sensor-based device placed between the needle and the syringe holding the medication. EpiFinder sends a signal confirming when the needle tip has successfully reached the epidural space. Will they use it? In a clinical study of EpiFinder involving 31 Israeli patients, physicians delivered the epidural accurately every time, demonstrating the device’s safety and effectiveness. The participating doctors gave Omeq valuable feedback on refining the device and expressed their satisfaction with EpiFinder’s ease of use and benefits. This is critical, Margalit points out, in assuring the device will be adopted in what is estimated to be a $1 billon market. A physician preparing to do an epidural injection. Photo by Ravipat via Shutterstock.com
“Clinical literature shows that a significant percentage of all epidural insertions are initially misplaced,” said Omeq’s medical director, Dr. David Gichtin, senior anesthesiologist at Baltimore’s Johns Hopkins Hospital. “While most of these are corrected procedurally without adverse events, a meaningful number of complications … result in patient suffering and substantial institutional costs,’ Gichtin said. “The EpiFinder smart device offers to improve the performance of epidural technique for potentially better outcomes, with the intent to make epidural procedures safer and easier for doctors and patients.”
Series A starting
A portfolio company of The Trendlines Group , Omeq Medical has been supported by Israeli Innovation Authority grants and is beginning a Series A funding round toward commercialization. “Our current discussions include major US anesthesia product distributors, strategic partners and investors,” said Omeq Medical Chairman Carl Rickenbaugh, who has 30-plus years of executive experience in the medical-device space with companies such as CR Bard and Abbott Laboratories. “We are now doing premarket activities ahead of a limited US launch early next year,” Margalit tells ISRAEL21c. And even though the device already has FDA clearance, Margalit plans to provide further clinical data by conducting a large multicenter study in the United States to show how the EpiFinder device improves performance and successful placement. Because the same technology could be used to assist in the accurate delivery of any medical instrument to any specific anatomical region, Margalit adds, Omeq will be exploring other clinical indications for its future pipeline. The first will likely be orthopedic injections. For more information, click here . ADVERTISEMENT

InnovationSmart device aims to improve safety of epidurals Abigail Klein Leichman

Omeq Medical bags FDA approval for epidural guidance device
aellison
Fri, 05/12/2023 - 11:30

Omeq Medical bags FDA approval for epidural guidance device

Omeq Medical receives FDA regulatory clearance for its smart device for epidural injections
Potential to become the standard of care for safer epidural injections. 9 May 2023
Medtech
Omeq Medical announced today that it has received regulatory clearance from the United States Food and Drug Administration (“FDA”) for its EpiFinder, which assists physicians to accurately position an epidural needle while performing the standard Loss of Resistance (“LOR”) technique. Since the 1920’s, epidurals have been performed utilizing the LOR technique, dependent upon the clinician’s experience, dexterity, and tactile feedback to identify a narrow 4-5 mm space. In up to 30% [1] [2] of cases the procedure initially fails. Furthermore, in up to 5+% [3] of cases, the needle tip inadvertently tears the protective sac surrounding the spinal fluid (a wet tap) leading to severe headache and possible neurological complications. EpiFinder is the first real improvement of this technique since its inception. It provides physicians with an additional signal identifying the epidural space. EpiFinder is a sensor-based, battery-operated single-use epidural placement device for safe, accurate epidural injections. The simple, easy-to-use device fits between a standard needle and syringe, requires no capital equipment, and is compatible with standard epidural syringes on the market. The device integrates seamlessly with the standard LOR technique and monitors tissue resistance at the needle tip to accurately detect needle penetration into the epidural space, protecting the patient from complications associated with misplacement. Omeq conducted a first-in-human clinical study to demonstrate the safety and effectiveness of EpiFinder. The study results confirmed that Omeq’s solution is safe and reliable to use to accurately place an epidural needle. During the study the participating physicians were able to safely provide successful epidural block in 100% of the thirty-one (31) patients while using the device, commenting positively on the ease of use and the benefits that the device offers. [1] J. Hermanides, M.W. Hollmann et al. “Failed epidural: causes and management”, British Journal of Anaesthesia, Volume 109, Issue 2, August 2012, Pages 144-154
[2] Joshua H. Levin et al. “The Importance of Image Guidance during Epidural Injections: Rates of Incorrect Needle Placement during Non-Image Guided Epidural Injections, J Spine 2012, 1:2
[3] Christopher Allen-John Webb, “Unintentional dural puncture with a Tuohy needle increases risk of chronic headache”, Anesth Analg. 2012 Jul;115(1):124-32. Clinical literature shows that a significant percentage of all epidural insertions are initially misplaced. While most of these are corrected procedurally without adverse events, a meaningful number of complications such as post-procedure headaches from dural puncture, nerve injury, inadequate pain relief, result in patient suffering and substantial institutional costs. The EpiFinder smart device offers to improve the performance of epidural technique for potentially better outcomes, with the intent to make epidural procedures safer and easier for doctors and patients. David Gichtin M.D., senior anesthesiologist at the Johns Hopkins Hospital and Omeq’s medical director
We are grateful to the anesthesia community that has supported our development. We now turn our focus to bring EpiFinder to US patients receiving epidural injections. EpiFinder offers the potential to become the new standard of care while performing LOR. The procedure today is performed by advancing the epidural needle forward until the clinician senses a loss of resistance indicative that the epidural space in the spine has been reached. Using the same procedure, EpiFinder adds a second independent objective signal that the epidural space has been reached. Our initial clinical experience indicates that clinicians’ targeting, and placement is accurate with the EpiFinder. Lior Margalit, CEO Omeq Medical
With the FDA’s US marketing clearance achieved, we are excited to accelerate our discussions with the anesthesia community to bring this exciting development to market for the benefit of US patients. Our current discussions include major US anesthesia product distributors, strategic partners, and investors. We encourage interested parties to contact us directly. Carl Rickenbaugh, Chair Omeq Medical, former VP M&A at Bard Peripheral Vascular & Biopsy
See More News

Omeq Medical receives FDA regulatory clearance for its smart device for epidural injections

EpiFinder is a sensor-based, battery-operated single-use epidural placement device that helps physicians for accurately positioning an epidural needle while performing the standard Loss of Resistance (LOR) technique
FDA approves Omeq’s EpiFinder smart device. (Credit: Diana Polekhina on Unsplash)
Omeq Medical, a portfolio company of Israel-based Trendlines Group, has received the US Food and Drug Administration (FDA) approval for its EpiFinder smart device. EpiFinder is a sensor-based, battery-operated single-use epidural placement device, intended for safe and accurate delivery of epidural injections. It helps physicians in accurately positioning an epidural needle while performing the standard Loss of Resistance (LOR) technique. EpiFinder is a simple, easy-to-use device that fits between a standard needle and syringe, requires no capital equipment, and is compatible with standard epidural syringes. Also, the device can be easily integrated with the standard LOR technique and monitors tissue resistance at the needle tip to accurately detect needle penetration into the epidural space. It protects the patient from complications arising from misplacement, said the medical device company. Omeq Medical chairman Carl Rickenbaugh said: “With the FDA’s US marketing clearance achieved, we are excited to accelerate our discussions with the anesthesia community to bring this exciting development to market for the benefit of US patients. “Our current discussions include major US anesthesia product distributors, strategic partners, and investors. We encourage interested parties to contact us directly.”
Omeq medical director and senior anesthesiologist at Johns Hopkins Hospital, David Gichtin said: “The EpiFinder smart device offers to improve the performance of epidural technique for potentially better outcomes, with the intent to make epidural procedures safer and easier for doctors and patients.”
Historically, epidurals have been performed using the LOR technique, which depends upon the clinician’s experience, dexterity, and tactile feedback to identify a narrow 4-5mm space. The procedure initially fails in up to 30% of cases, and the needle tip inadvertently tears the protective sac surrounding the spinal fluid in more than 5% of cases. It leads to severe headache and possible neurological complications in patients. Omeq said that its EpiFinder provides physicians with an additional signal to identify the epidural space and is the first real improvement of this technique. The company has conducted a first-in-human clinical study, which confirmed the safety and effectiveness of EpiFinder, for accurately placing an epidural needle . Omeq Medical CEO Lior Margalit said: “We are grateful to the anesthesia community that has supported our development. We now turn our focus to bring EpiFinder to US patients receiving epidural injections. “EpiFinder offers the potential to become the new standard of care while performing LOR. The procedure today is performed by advancing the epidural needle forward until the clinician senses a loss of resistance indicative that the epidural space in the spine has been reached. “Using the same procedure, EpiFinder adds a second independent objective signal that the epidural space has been reached. Our initial clinical experience indicates that clinicians’ targeting, and placement is accurate with the EpiFinder.”
Do you have interesting content to share with us? Enter your email address so we can get in touch. Related Article

Omeq Medical secures FDA approval for EpiFinder smart device

Unattributed

Omeq Medical is focused on developing devices for epidural injections. Its product, the EpiFinder, is a device that measures tissue resistance at the needle tip to confirm needle placement during epidural procedures. Its device integrates with standard epidural injection kits and provides a signal related to the loss of resistance technique. It was founded in 2011 and is based in Misgav, Israel.

Date	Round	Amount	Investors	Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.	Revenue	Sources
1/30/2019	Unattributed	$3M	Pharos Innovations	$XXM	0 FY undefined	1
7/22/2013	Seed	$XXM	Subscribe to see more	$XXM	0 FY undefined	10
	Other Investors		Subscribe to see more	$XXM	0 FY undefined	10

Date	1/30/2019	7/22/2013
Round	Unattributed	Seed	Other Investors
Amount	$3M	$XXM
Investors	Pharos Innovations	Subscribe to see more	Subscribe to see more
Valuation	$XXM	$XXM	$XXM
Revenue	0 FY undefined	0 FY undefined	0 FY undefined
Sources	1	10	10

First funding	Last Funding	Investor	Rounds	Type	Location
1/30/2019	1/30/2019	Pharos Innovations	1 Unattributed	Corporation	Illinois
00/00/0000	00/00/0000	Misgav Venture Accelerator	Subscribe to see more	Incubator/Accelerator	Israel
		The Trendlines Group	Subscribe to see more	Venture Capital	Israel

First funding	1/30/2019	00/00/0000
Last Funding	1/30/2019	00/00/0000
Investor	Pharos Innovations	Misgav Venture Accelerator	The Trendlines Group
Rounds	1 Unattributed	Subscribe to see more	Subscribe to see more
Board Seats
Type	Corporation	Incubator/Accelerator	Venture Capital
Location	Illinois	Israel	Israel

How VCs Use CB Insights

Professional Services

Platform Overview

Omeq Medical

Total Raised

Investors Count

Funding, Valuation & Revenue

Omeq Medical Investors